Ancillary testing for some specific tumours (e.g. SMARCA4-deficient (lung) adenocarcinoma–which is typically TTF-1 negative) is not available or not done routinely on brain metastatic specimens (e.g. lung biomarker panel); this limits the ability of the pathologist to classify some tumours. This evidence concerns the gene TTF1 and neoplasm.